NCT06260722

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,250 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Retatrutide	Administered SC.
DRUG	Semaglutide	Administered SC.

Timeline

• Start date: 2024-02-21
• Primary completion: 2026-08-01
• Completion: 2027-01-01
• First posted: 2024-02-15
• Last updated: 2026-04-13

Locations

77 sites across 5 countries: United States, Argentina, Canada, Mexico, Puerto Rico

Regulatory

• FDA-regulated drug study